Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Customer Focus - Physician/Prescribing

Sponsored by

Finalist

A new chapter in Dupuytren's contracture treatment

Pfizer in association with FTI Consulting


Summary of work

An innovative medical education programme helped Pfizer introduce the first pharmaceutical product to a disease area and customer group – comprising physicians treating hand disorders – that was already satisfied with established surgical techniques. 

XIAPEX, an injectable treatment for Dupuytren’s contracture in adult patients with a palpable cord, was launched by Pfizer in Europe in March 2011 as an alternative for patients. Market research shows many patients refer to surgery as a “last resort”.  

In a risk-averse regulatory environment, Pfizer recognised the need to develop a formal training programme, as the treatment procedure is unlike surgical intervention and the injection must be precise to protect patients by avoiding serious adverse events. 

The core training programme, including a detailed brochure, video and online course, was developed with Europe’s foremost hand specialists and helped secure marketing authorisation in February 2011. The programme was disseminated via a peer-to-peer education cascade, involving training workshops, symposia and development of a bespoke training model. 

Knowledge of XIAPEX and interest in introducing it into clinical practice have increased dramatically, with over 2,000 hand, orthopaedic and plastic surgeons in 13 countries trained how to use XIAPEX in 2011 alone. Customer feedback on the training programme has been consistently excellent.

 

 

Executive summary as submitted


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics